


IO Biotech Appoints Heidi Hunter to its Board of Directors
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315
Promising clinical results showed clearance of basal cell carcinoma…

4SC provides Q2 2023 and H1 2023 update
Positive topline data for resminostat in RESMAIN pivotal…

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference
STORM’s lead programme is the first RNA methyltransferase inhibitor…

Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models
Sarcopenia – age-related loss of muscle mass and strength…

Futura Medical – MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance
Novo Holdings today announced it has participated in the EUR…

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition
Pre-clinical data strongly supports progression of a METTL3 inhibitor…

IO Biotech, Inc. Announces $75 Million Private Placement Financing
Offering includes participation from both new and existing healthcare-dedicated…

Biocomposites appoints two new Directors to strengthen its team for its next phase of growth
Michelle Lewis becomes Human Resources Director
Ciara Airey…

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
Total deal size of approximately ~$650M, including over $150M…

Invizius receives MHRA approval to commence First-in-Human clinical study of H-Guard® Priming Solution
Invizius Limited (“Invizius”), a biotechnology company developing…

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq:…

Medicxi Announces $400m Medicxi IV
Fund to focus on its pioneering ‘asset-centric’ investment…

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Collaboration to advance development of innovative oral small…

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer
Newly appointed CEO has over 20 years’ experience in company…

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
Eric Faulkner, currently Sr. Vice President, CMC, appointed…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York